Please login to the form below

Not currently logged in
Email:
Password:

LAMA/LABA

This page shows the latest LAMA/LABA news and features for those working in and with pharma, biotech and healthcare.

AZ prepares to file COPD triple, taking on rival GSK

AZ prepares to file COPD triple, taking on rival GSK

The data reveals that the drug was better than two-drug combinations in preventing COPD exacerbations, reducing attacks by 52% compared to AZ’s LAMA/LABA combination Bevespi (glycopyrronium/formoterol fumarate). ... There’s still all to play for, and

Latest news

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    The real battleground between the two companies is expected to be three-drug combinations for COPD, with an inhaled corticosteroid (ICS) added to the LAMA/LABA duo. ... 2019. Given that the AERISTO trial compared the LAMA/LABA backbones of GSK and AZ’s

  • GSK files first application for triple COPD therapy GSK files first application for triple COPD therapy

    The therapy is a single device delivering inhaled corticosteroid (ICS) fluticasone furoate, long-acting beta agonist (LABA) vilanterol and long-acting muscarinic antagonist (LAMA) umeclidinium - covering the three most widely-used ... GSK's head of

  • GSK's triple COPD therapy tops Symbicort in phase III trial GSK's triple COPD therapy tops Symbicort in phase III trial

    The phase III FULFIL trial compared the once-daily triple therapy - consisting of corticosteroid fluticasone furoate, long-acting muscarinic antagonist (LAMA) umeclidinium and long-acting beta agonist (LABA) vilanterol - to Symbicort, ... LAMA, LABA and

  • Boehringer COPD drug 'could give patients more independence' Boehringer COPD drug 'could give patients more independence'

    Boehringer needs Spiolto to hit the ground running as its faces increasing competition in the COPD market, with a number of other LAMA/LABA combinations jostling for elbow room in the

  • Novartis sales dip, but all eyes are on Entresto Novartis sales dip, but all eyes are on Entresto

    In its respiratory portfolio, Novartis said long-acting muscarinic antagonist/long-acting beta agonist (LAMA/LABA) product Ultibro (indacaterol and glycopyrronium bromide) added $66m to its coffers, three times the sales ... Pharma chief David Epstein

More from news
Approximately 2 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics